We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

AUREOMYCIN TREATMENT OF PNEUMOCOCCIC PNEUMONIA Clinical and Laboratory Studies on Thirty-Three Patients

Arch Intern Med (Chic). 1949;84(6):857-874. doi:10.1001/archinte.1949.00230060014002.
Text Size: A A A
Published online


AUREOMYCIN is an antibiotic which, from the results of early studies in vitro and in experimental infections, as well as in initial clinical trials, appears to have a wider range of activity than its successful antecedents, penicillin and streptomycin.1 This range encompasses most of the known causative agents of the acute pneumonias, including the gram-positive and gram-negative bacteria, the organisms of the psittacosis-lymphogranuloma venereum group and the Q fever and other rickettsias. Since aureomycin was also found to be effective when given by mouth and was essentially free of serious toxic effects, it seemed particularly suitable for extended clinical trials in cases of pneumonias of diverse origin. During the past year an attempt was therefore made to evaluate the therapeutic effectiveness of aureomycin in the various types of pneumonia and in some of the other severe acute infections of the respiratory tract that were available for study. The present


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.